ATYR1940 SECOND SAFETY EXTENSION (006) TRIAL: PHASE 1B/2

In the second quarter of 2016, we initiated a long-term extension study for patients from our 003 and 004 studies. This multinational, multi-center, open-label extension study is designed to assess the long-term safety, effects on muscle, PD and systemic exposure of ATYR1940 in adult FSHD, early-onset FSHD, and LGMD2B patients from our 003 and 004 studies.

Data Release
 
Clinicaltrials.gov

© 2007 - 2018   aTyr Pharma.   Legal   Privacy Policy